North East and North Cumbria
ICS Formulary
ICS Formulary
13 Skin
Specials Recommended by the British Association of Dermatologists for Skin Disease
Most prescribing uses licensed medicines whose safety and efficacy are assured. For many common dermatological diseases including psoriasis and eczema, the range of licensed medicines is limited. As a result, Dermatology prescribing may rely significantly on unlicensed creams and ointments (known as ‘Specials’) containing tars, dithranol, salicylic acid, steroids and other active constituents in a range of concentrations and bases. This is of particular concern in primary care where lack of effective price controls and a mechanism to ensure independent scrutiny of product quality has increased costs and concern about standards. To address these concerns, and help optimise quality of care, adherence to the revised British Association of Dermatologists (BAD) list of preferred Specials (2018) is encouraged.
13-05-03 Drugs affecting the immune response
| Abrocitinib Cibinqo® |
|
Formulary
|
|
 MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
| Adalimumab |
|
Formulary
|
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of |
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
|
|
| Apremilast Otezla® |
|
Formulary
|
|
|
MHRA Drug Safety Update (Jan 2017): Apremilast (Otezla ): risk of suicidal thoughts and behaviour NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
|
|
| Bimekizumab Bimzelx® |
|
Formulary
|
|
|
NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis |
|
|
| Brodalumab Kyntheum® |
|
Formulary
|
|
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
|
|
| Certolizumab pegol |
|
Formulary
|
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
|
|
| Ciclosporin |
|
Formulary
|
|
|
County Durham and Darlington Shared Care Guideline: Ciclosporin Tees Valley Shared Care Guideline: Ciclosporin |
|
| Deucravacitinib Sotyktu |
|
Formulary
|
|
|
NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis |
|
|
| Dimethyl fumarate Skilarence® |
|
Formulary
|
|
|
NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
|
|
| Dupilumab Dupixent® |
|
Formulary
|
|
|
MHRA Drug Safety Upate (Nov 2022): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
|
|
| Etanercept Enbrel®, Benapali® & Erelzi® |
|
Formulary
|
Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of |
|
NICE TA103: Psoriasis - efalizumab and etanercept NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
|
|
| Guselkumab Tremfya® |
|
Formulary
|
|
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
|
|
| Infliximab Remsima®, Inflectra®, Remicade® |
|
Formulary
|
|
|
NICE TA134: Infliximab for psoriasis |
|
|
| Ixekizumab Taltz® |
|
Formulary
|
|
|
NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis |
|
|
| Pimecrolimus cream Elidel® |
|
Formulary
|
|
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
|
| Risankizumab Skyrizi® |
|
Formulary
|
|
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
|
|
| Secukinumab Cosentyx® |
|
Formulary
|
|
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people NICE TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa |
|
|
| Tacrolimus ointment Protopic® |
|
Formulary
|
|
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
|
|
| Tildrakizumab Ilumetri® |
|
Formulary
|
|
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
|
|
| Tralokinumab Adtralza® |
|
Formulary
|
|
|
MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
|
| Upadacitinib Rinvoq® |
|
Formulary
|
|
|
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
|
| Ustekinumab Stelara® |
|
Formulary
|
|
|
MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis NICE TA180: Psoriasis - ustekinumab (Updated March 2017) NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
|
|
| Baricitinib Olumiant® |
|
Non Formulary
|
|
|
NICE TA926: Baricitinib for treating severe alopecia areata |
|
Links
- NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
- County Durham and Darlington Shared Care Guideline: Ciclosporin
- County Durham and Darlington Shared Care Guideline: Hydroxychloroquine
- County Durham and Darlington Shared Care Guideline: Methotrexate
- County Durham and Tees Valley Guidance for Prescribing and Monitoring in Post Bariatric Surgery in Primary Care
Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities- MHRA Drug Safety Upate (Nov 2022): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA Drug Safety Upate (Nov 2022): Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (Aug 2020): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
- MHRA Drug Safety Update (Feb 2022): Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis
- MHRA Drug Safety Update (Jan 2017): Apremilast (Otezla ): risk of suicidal thoughts and behaviour
- MHRA Drug Safety Update (Mar 2020): Baricitinib (Olumiant▼): risk of venous thromboembolism
- MHRA Drug Safety Update (Sept 2020): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing
- NICE CG153: Psoriasis: assessment and management
- NICE TA103: Psoriasis - efalizumab and etanercept
- NICE TA134: Infliximab for psoriasis
- NICE TA146 Adalimumab for the treatment of adults with psoriasis
- NICE TA180: Psoriasis - ustekinumab (Updated March 2017)
- NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
- NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
- NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
- NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
- NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
- NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
- NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
- NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
- NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis
- NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
- NICE TA81: Frequency of application of topical corticosteroids for atopic eczema
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
- NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
- NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis
- NICE TA926: Baricitinib for treating severe alopecia areata
- NICE TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa
- NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
- North of Tyne, Gateshead and North Cumbria - Hydroxychloroquine Shared Care Guidance v5 (October 2022)
- North of Tyne, Gateshead and North Cumbria - Management of patients, post-bariatric surgery in primary care
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence
- Tees Valley Shared Care Guideline: Ciclosporin
- Tees Valley Shared Care Guideline: Methotrexate